ABT-737

Catalog No.S1002

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Cited by 101 Publications

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )

J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )
Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )
Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )

Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )
Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Features

First-generation inhibitor of anti-apoptotic Bcl-2 proteins.

Targets

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. ^[1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. ^[2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. ^[3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. ^[4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	M2rMfmNmdGxiVnnhZoltcXS7IFHzd4F6	NGLFU3gzPTBibl5CpC=>	MkHaO\|IhcA>?	NYC5OXVvTE2VTx?=	NYr4VnU1[2G3c3XkJFk4LSCub4PzJI9nKH[rYXLpcIl1gSCrbjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKEKFTE[gd4lTVkF?	NVXaZ3hVOjZ4NUeyPFg>
KG1a	M2Pnb2NmdGxiVnnhZoltcXS7IFHzd4F6	NEDXWYsxNTFyIN88US=>	MXeyOEBp	NVvX[GIxTE2VTx?=	M3WyV2lEPTB;Nz62PEDPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MkLCNlY2PTJ5MUK=
Kasumi-1	MoDvR4VtdCCYaXHibYxqfHliQYPzZZk>	NYrDTFlrOC1zMDFOwG0>	M{L1bVI1KGh?	NEHVSnNFVVOR	NXLzT4pQUUN3ME20Mlg4KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MlHyNlY2PTJ5MUK=
KG1a	NUD6OIV1SXCxcITvd4l{KEG\|c3H5	M{mxclAuOTBizszN	NV2zcVRGOjRiaB?=	NUT4N\|R4TE2VTx?=	MYTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NHH3O3kzPjV3MkexNi=>
Kasumi-1	NHPMeI1CeG:ydH;zbZMhSXO\|YYm=	NHy3SpkxNTFyIN88US=>	MkfkNlQhcA>?	NU[wUlNqTE2VTx?=	M{LpNolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NG\0cFAzPjV3MkexNi=>
MC-3	NUXjPJR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NECzd5Q2NzFyL{KwJO69VQ>?	NGjncHEzPCCq	Mke2SG1UVw>?	NUTNcZE6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MVmyOlQ1PzZzNR?=
HN22	NFLOW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWG1[o13Oi53L{euOU8zOi53IN88US=>	NFnmVHgzPCCq	MY\EUXNQ	M2rveIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MkLNNlY1PDd4MUW=
MC-3	NHr2NFBCeG:ydH;zbZMhSXO\|YYm=	NWP1UlZOPS9zMD:yNEDPxE1?	MV:yOEBp	MmjsSG1UVw>?	M2HJ[Ylv\HWlZYOgZ4F{eGG\|ZT3t[YRq[XSnZDDhdI9xfG:\|aYO=	M1HoTlI3PDR5NkG1
HN22	MV;BdI9xfG:\|aYOgRZN{[Xl?	NXfLOYpQOi53L{euOU8zOi53IN88US=>	M1TXT\|I1KGh?	M3;IXmROW09?	MmHvbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?=	MWCyOlQ1PzZzNR?=
MOLT-4	M4nme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfBNVAuPTByMDDuUS=>	MkLEO\|IhcA>?	Mn\3SG1UVw>?	MU\JR\|UxRTBwMUm4JO69VQ>?	MYWyOlM6OjN\|Mh?=
RS4;11	NUO0XYliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOxNE02ODByIH7N	MnXZO\|IhcA>?	NHHHZ21FVVOR	NWTxUHhXUUN3ME2wMlAxOiEQvF2=	NFGxOFIzPjN7MkOzNi=>
JURKAT	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XEUFExNTVyMECgcm0>	NYPRZXlpPzJiaB?=	Ml;3SG1UVw>?	Mm[1TWM2OD14NjFOwG0>	NFvMPYozPjN7MkOzNi=>
CEM R	M2rISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYOwbnQ2OTBvNUCwNEBvVQ>?	MoOzO\|IhcA>?	M2T2[WROW09?	MnzkTWM2OD13LkSg{txO	NGT4UpIzPjN7MkOzNi=>
CEM S	M3X1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvBfGxHOTBvNUCwNEBvVQ>?	NWnBfGJYPzJiaB?=	MY\EUXNQ	NWm0UVlIUUN3ME2xNk4yKM7:TR?=	MVyyOlM6OjN\|Mh?=
MOLT-4	MXfBdI9xfG:\|aYOgRZN{[Xl?	M2PGVFExNTFyMECgcm0>	MXWyOEBp	M3PhWGROW09?	MofPZ4F2e2W\|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG=	M4rBPVI3Ozl{M{Oy
CEM S	Mmr4RZBweHSxc3nzJGF{e2G7	MVKxNE0yODByIH7N	NV\WdZFkOjRiaB?=	Mm\GSG1UVw>?	NFjMVm9k[XW\|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=>	MUWyOlM6OjN\|Mh?=
JURKAT	NY\6b4lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjaflh6OTByLUGwNFAhdk1?	MWi0PEBp	NUXJfGFYTE2VTx?=	NV7xXo5kUUN3ME25OVXDuTlwMzDuUS=>	MkDlNlYyPzJ{Nkm=
LOUCY	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVOxNFAuOTByMDDuUS=>	M2nSNVQ5KGh?	MVzEUXNQ	M2\VN2lEPTB;M{KuPOKyOTBwOTDuUS=>	NHrpdVIzPjF5MkK2PS=>
WM-115	NYrlPVkxS2WubDDWbYFjcWyrdImgRZN{[Xl?	MV6xNFDDqG6P	Ml7XO\|IhcA>?		NH\mSotmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?=	NHfMVJQzPjFzNke3Oi=>
B16	MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MnXYNVAxyqCwTR?=	M1ThVlczKGh?		MVrlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>?	NUTHPZVrOjZzMU[3O\|Y>
HL-60	NYTtSJhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWS3NkBp		MmHpTWM2OMLiPTCxNE44KG6P	Ml;1NlYxPDV4MEm=
MOLM-13	NWfmeWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVe3NkBp		M3HFWmlEPTEEoE2gNlcvQSCwTR?=	M{XPOVI3ODR3NkC5
OCI-AML3	NI\hbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXHGPGlIPzJiaB?=		M4PyfWlEPTEEoE2gNVk2OCCwTR?=	NYXz[HJpOjZyNEW2NFk>
BCWM.1	NGruN45CeG:ydH;zbZMhSXO\|YYm=	NHfqbHgxNTFwNjFOwG0>	NWPleolmOjRiaB?=		M{HycYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NYT3NoZpOjV6OUOyPVA>
MWCL-1	NHG2e5lCeG:ydH;zbZMhSXO\|YYm=	NVnleZVmOC1zLk[g{txO	MXyyOEBp		MoHFbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MkXkNlU5QTN{OUC=
MM.1s	MXPBdI9xfG:\|aYOgRZN{[Xl?	MYCwMVEvPiEQvF2=	M1L0flI1KGh?		Mk\abY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MWeyOVg6OzJ7MB?=
HCT116	NH3QUG1HfW6ldHnvckBCe3OjeR?=	MUizM\|ExKM7:TR?=	NHXr[FgyOsLiaNMg	MknXSG1UVw>?	NFHLd45qdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hVEN\|Qj3JTUBkd264ZYLzbY9vKGGwZDDTVXNVVTFiZHXndoFl[XSrb36=	NEPDXXczPTdzNUCyPC=>
HCT116 BAX BAK1 DKO	M{DETGZ2dmO2aX;uJGF{e2G7	NEmwWJg{NzFyIN88US=>	MmPyNVLDqGkEoB?=	NET1OnNFVVOR	M3PPNolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG\|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?=	MY[yOVcyPTB{OB?=
HCT116	MUPGeY5kfGmxbjDBd5NigQ>?	NUXDUmFKOTBizszN	MnzhNVLDqGkEoB?=	M1\VSGROW09?	MmK2bY5kemWjc3XzJGdHWC2OQ{PCJJB2dmO2YR?=	NYL0PJBkOjV5MUWwNlg>
HCT116 BAX BAK1 DKO	NGrIV\|RHfW6ldHnvckBCe3OjeR?=	NV3ifmNwOTBizszN	M1fFTFEzyqCqwrC=	M1vmTmROW09?	M36zXYlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG=	NGHqbWQzPTdzNUCyPC=>
HCT116	NV[yVZF7SXW2b4DoZYd6KEG\|c3H5	NX7mSpZoOTBizszN	NGXCdG4yOsLiaNMg	NXHKbG9FTE2VTx?=	M4TBfYlv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm	MUKyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO	MnLFRZV1d3CqYXf5JGF{e2G7	NIHmbZcyOCEQvF2=	M1X0SVEzyqCqwrC=	M3fuOGROW09?	NWT1Z21ycW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V?	MXiyOVcyPTB{OB?=
U937	MortRZBweHSxc3nzJGF{e2G7	MoX0NE4yOjVvMjFOwG0>	NY[0boNXOjRiaB?=		MmSx[Y5p[W6lZYOgSGhCN1hvMUGtbY5lfWOnZDDhdI9xfG:\|aYO=	NWj4b3hsOjV5MUSwNlQ>
U937	NG\RN49CeG:ydH;zbZMhSXO\|YYm=	MWWwMlUh\|ryP	NHSzOWgzPCCq		M3LVRoVvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCgZY5lKGOjc4Dhd4UuOyCjczD3[YxtKGG\|IF7vfIEhdGW4ZXy=	NXG0O2hkOjV5MUSwNlQ>
HL-60 AAA-Bcl-2	MWnBdI9xfG:\|aYOgRZN{[Xl?	NXTMbotMOC13IN88US=>	NYThfI9SPDhiaB?=		MlzjTWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NEP5VGQzPTdzMUS2NC=>
HL-60 EEE-Bcl-2	NX\zd\|EySXCxcITvd4l{KEG\|c3H5	M3XVVlAuPSEQvF2=	NXfLSnZuPDhiaB?=		NWPROphEUUN3ME21JO69de,:jDDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MX:yOVcyOTR4MB?=
U87	NV70XJVvTnWwY4Tpc44hSXO\|YYm=	M1v4NFUxKM7:TR?=	MWqyOEBp		NYP0VnFxemWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=>	MmPSNlU3Pjd4NkO=
K562	NHW4ZZNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NITvSFgyNTFyIN88US=>	NGnGb4Q1QCCq	M2D3c2ROW09?	M2DYTWlEPTB;Mk[uO{DPxE1?	Ml[zNlU2QTZ3NkG=
K562/Mcl -1-IRESBim	NVz4UlhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTlwMzFOwG0>	M4m5eVI2PTN3OUCw
K562/Bcl- 2-IRESBim	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrwdYdKSzVyPUCuN\|Uh\|ryP	NUXBOWk3OjV3M{W5NFA>
Jurkat	NXXUVYtjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzZ[oQyUUN3ME2wMlY3KM7:TR?=	NVK5OHFDOjV3M{W5NFA>
JurkatΔBak	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInhVJJKSzVyPkWwJO69VQ>?	MnLnNlU2OzV7MEC=
HL60/VCR	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2CzbGlEPTB-MUCwJO69VQ>?	MlzxNlU2OzV7MEC=
Kasumi-1	NHz5W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTBwMEGg{txO	MUiyOVU{PTlyMB?=
Kasumi-1/ABT	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITCbWpKSzVyPUCuOVEh\|ryP	MWKyOVU{PTlyMB?=
THP-1	M1jkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[xW4xKSzVyPUGuNlch\|ryP	MmS4NlU2OzV7MEC=
U937	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXK0VZA{UUN3ME21MlI6KM7:TR?=	Ml\nNlU2OzV7MEC=
C1498	NF;SbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUT5b2hkUUN3ME22MlE{KM7:TR?=	NVTHcld7OjV3M{W5NFA>
RPMI 8226	NUPrbmZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfvTWM2OD1yLkK1JO69VQ>?	M2LmZ\|I2PTN3OUCw
MM.1S	NF\ZTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTBwNECg{txO	Mkf4NlU2OzV7MEC=
NCI-H929	NInCeIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWq4S5BbUUN3ME2xOU4zOSEQvF2=	MWSyOVU{PTlyMB?=
U266	Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjVSotKSzVyPUCuOlgh\|ryP	M{nrT\|I2PTN3OUCw
MCF-7	NVLT[ZcyS2WubDDWbYFjcWyrdImgRZN{[Xl?	MWm1JO69VQ>?	MX[0PEBp	MX7EUXNQ	MoDa[Y5p[W6lZYOgeIhmKHOnboPpeIl3cXS7IITvJI9zKHKjZHnheIlwdg>?	MnPhNlU1ODlzMkS=
MCF-7	NYnlUGVUSXCxcITvd4l{KEG\|c3H5	NUPMem9RPSEQvF2=	MnP2OE8zPC92ODDo	M4TPfWROW09?	Mn\LbY5kemWjc3XzJJRp\SClbHXheoVlKFCDUmC=	NXi3emV7OjV2MEmxNlQ>
MCF-7	M{\TdGZ2dmO2aX;uJGF{e2G7	MX:1JO69VQ>?	NYTZSJRrOjRiaB?=	NGO0fmpFVVOR	M3KySYVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	M4exRlI2PDB7MUK0
MDA-MB 231	M1jnTmZ2dmO2aX;uJGF{e2G7	NVrYTnZ6PSEQvF2=	M{PTb\|I1KGh?	Mm\NSG1UVw>?	MVLlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	MY[yOVQxQTF{NB?=
ZR-75-1	MoTnSpVv[3Srb36gRZN{[Xl?	NFXSfVI2KM7:TR?=	MWqyOEBp	NHrjS3BFVVOR	MVPlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	MWWyOVQxQTF{NB?=
A549	NVHLbXdyS2WubDDWbYFjcWyrdImgRZN{[Xl?	MnT6NE0zOCEQvF2=	NVvmeIhSPzJiaB?=	MVHEUXNQ	M2\YUIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	M{W1Z\|I2Ozh6N{[y
H1299	MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MV:wMVIxKM7:TR?=	MkewO\|IhcA>?	M4rFN2ROW09?	MnTD[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	MnPINlU{QDh5NkK=
HO-8910	NWjoO2VRS2WubDDWbYFjcWyrdImgRZN{[Xl?	MXmwMVIxKM7:TR?=	NYr6Uo8{PzJiaB?=	NXPUe2oyTE2VTx?=	NXXQ[4RY\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	MVmyOVM5QDd4Mh?=
HT-29	M1zTeWNmdGxiVnnhZoltcXS7IFHzd4F6	NWjJWZFtOC1{MDFOwG0>	NWPXXYxUPzJiaB?=	NGfZNG5FVVOR	Mnvy[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	M4DPcFI2Ozh6N{[y
HCT-116	NY\3W5RyS2WubDDWbYFjcWyrdImgRZN{[Xl?	MUCwMVIxKM7:TR?=	MmXmO\|IhcA>?	MXXEUXNQ	MnX4[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	M12yRlI2Ozh6N{[y
A549	M{\6O2Fxd3C2b4Ppd{BCe3OjeR?=	NUTQTJpXOjBizszN	NXPjWZNrPDhiaB?=	MkLhSG1UVw>?	M{\MU4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu	MVSyOVM5QDd4Mh?=
H1299	MoGwRZBweHSxc3nzJGF{e2G7	M1LjPFIxKM7:TR?=	M4TmelQ5KGh?	NFj6d3dFVVOR	NV3DPIk1cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG\|cHnybY4>	MUCyOVM5QDd4Mh?=
Sc-1	NHGzc3pE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MV:wMlAxODFvMTFOwG0>	M1XnbVk3KGh?		NHm4PXVl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M2nPTVI2Ozd\|NUC4
OcI-LY18	NWOwRm5PS2WubDDWbYFjcWyrdImgRZN{[Xl?	Moj4NE4xODBzLUGg{txO	NFPSb\|Q6PiCq		MoC2[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MnPtNlU{PzN3MEi=
RL	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2C1XVAvODByMT2xJO69VQ>?	NXTlSJpGQTZiaB?=		Mmnp[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NHz2bY4zPTN5M{WwPC=>
RKO	MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFGxe\|UxNTFyIN88US=>	MV:yOQKBkWkEoB?=	M1T1RWROW09?	NHqzXG9KSzVyPvMAjVI26oDLwsXN	NH63OGUzPTNyNEO4Ny=>
Caco-2	M2Pk[2NmdGxiVnnhZoltcXS7IFHzd4F6	NFvtO3IxNTFyIN88US=>	MlLKNlTjiImqwrC=	MV\EUXNQ	M4fpS2lEPTB;MUmuO-KBkcL3TR?=	MW[yOVMxPDN6Mx?=
DLD1	M{n0RWNmdGxiVnnhZoltcXS7IFHzd4F6	M2nJOVAuOTBizszN	NVXGT\|hGOjUkgJnoxsA>	NGfufI1FVVOR	NIXNd2pKSzVyPUG4Mlc56oDLwsXN	MXWyOVMxPDN6Mx?=
LS411N	Ml;2R4VtdCCYaXHibYxqfHliQYPzZZk>	MVmwMVExKM7:TR?=	M3zhWlI16oDLaNMg	NFzJOYNFVVOR	NWfsUJk3UUN3ME2xNU41P+LCidM1US=>	NI\uVnYzPTNyNEO4Ny=>
SW620	NYLiOpc3S2WubDDWbYFjcWyrdImgRZN{[Xl?	M1X3SFAuOTBizszN	MlXONlTjiImqwrC=	NHzVW4FFVVOR	Ml\RTWM2OD1zMj6yOQKBkcL3TR?=	NGrTdZYzPTNyNEO4Ny=>
HCT116	MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mlq4NE0yOCEQvF2=	MnjCNlTjiImqwrC=	M{nvfmROW09?	M33lRWlEPTB;MkCuOFnjiIoEtV2=	M2\0cFI2OzB2M{iz
HaCaT	MkHpR4VtdCCYaXHibYxqfHliQYPzZZk>	MUCwMlEwOS9zMDFOwG0>	MXWyOEBp	NXOxSZI3TE2VTx?=	MX7k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NEDYZZczPTJzMEe5OS=>
A5-RT3	MlfqR4VtdCCYaXHibYxqfHliQYPzZZk>	MWqwMlEwOS9zMDFOwG0>	Mlq1NlQhcA>?	M1rSTGROW09?	MWjk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NHfEU4MzPTJzMEe5OS=>
HaCaT	NW\TWGlCTnWwY4Tpc44hSXO\|YYm=	M3qwNlEx6oDLzszN	Ml3TNlQwPDhiaB?=	NFvNZ4lFVVOR	NGjpSnFqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36=	MY[yOVIyODd7NR?=
A5-RT3	MWHGeY5kfGmxbjDBd5NigQ>?	NXXYO\|JpOTEkgJpOwG0>	M1nxelI1NzR6IHi=	M{jOZWROW09?	Mn7lbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w	NWXkdHN6OjV{MUC3PVU>
A5-RT3	NEGzcplHfW6ldHnvckBCe3OjeR?=	NYXnbm1xPSEQvF2=	NGfSNoo3KGh?	M{myNWROW09?	MYHpcoR2[2W\|IITo[UBz\WynYYPlJI9nKG2rdH;jbI9v\HKrYXygdJJwfGWrboOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yC\|dYL2bZZidCCrbjDhJINie3Cjc3WtbY5l\XCnbnTlcpQhdWGwbnXy	MWSyOVIyODd7NR?=
U266	MYrGeY5kfGmxbjDBd5NigQ>?	MnXQOVAxNzd3MDDuUS=>	MXuyOE81QCCq	MWTEUXNQ	NIXzWYJld3ewcnXneYxifGW\|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm\|b3\vdo0>	M2e5cVI2OjB6OEi4
RPMI8226	NVHWRmxXTnWwY4Tpc44hSXO\|YYm=	NHjVWmw2ODBxN{WwJI5O	Mn23NlQwPDhiaB?=	Mn;ZSG1UVw>?	NUfPOHJE\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju	M1nY[lI2OjB6OEi4
MM.1S	NU\JSYk6TnWwY4Tpc44hSXO\|YYm=	NWPOVJhmPTByL{e1NEBvVQ>?	MWOyOE81QCCq	NUT0[3hCTE2VTx?=	M2r3cIRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=>	NYnj[XpkOjV{MEi4PFg>
Clone A	MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfX[IVbOC5{4pETOlAh\|ryP	MkLQO\|IhcA>?	M2TvemROW09?	MWnJR\|UxRTdwNTFOwG0>	Ml\4NlUzODh6OEK=
CX-1	NYjudoVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXiNE4z6oDVNkCg{txO	Mne1O\|IhcA>?	M{DScGROW09?	NWjzR4ZUUUN3ME2xMlgh\|ryP	MlvPNlUzODh6OEK=
LS174T	NX;6NHk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jJXlAvOuLCk{[wJO69VQ>?	NFzNOJM4OiCq	M4PVdGROW09?	NHvCSFNKSzVyPUG4MlMh\|ryP	NV7aTYFWOjV{MEi4PFI>
HT29	MX7BdI9xfG:\|aYOgRZN{[Xl?	M4\xdVEwPS9zMDFOwG0>	NF64NY41QCCq		NEDhN4xk[XW\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MX6yOVE6OjF6OB?=
SW480	NIn5Z\|ZCeG:ydH;zbZMhSXO\|YYm=	M{D6clEwPS9zMDFOwG0>	Ml\VOFghcA>?		NUjLfJJj[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MX2yOVE6OjF6OB?=
Colo205	NHW1enhCeG:ydH;zbZMhSXO\|YYm=	MVuxM\|UwOTBizszN	M13lVVQ5KGh?		M2nj[YNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NF7aSIozPTF7MkG4PC=>
Caco2	NHXtWmJCeG:ydH;zbZMhSXO\|YYm=	MVGxM\|UwOTBizszN	NELXeo81QCCq		NXHpTok5[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MXSyOVE6OjF6OB?=
PCI-13	M4SwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIfpZlk4OiCq	M{fIcmROW09?	MWTHTVUxRTF3INMxJFEvQCEQvF2=	NH[5flEzPTF\|OUO4Oy=>
PCI-15B	Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn7xO\|IhcA>?	MV3EUXNQ	M4rKW2dKPTB;MUGgxtEhPC53IN88US=>	MoPtNlUyOzl\|OEe=
UM-SCC22B	NWLheZpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGO3OJQ4OiCq	NVLLUGluTE2VTx?=	NYTCfJA1T0l3ME2xPUDDuSB{Lkmg{txO	NVfxRXRuOjVzM{mzPFc>
UM-SCC47	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWe3NkBp	MWfEUXNQ	NUfhZ4d4T0l3ME2xPUDDuSBzMj6zJO69VQ>?	MmfZNlUyOzl\|OEe=
93-VU-147T	NV;pXFl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnHOO\|IhcA>?	NEW0[JhFVVOR	MYXHTVUxRTRwMzFCtUA{NjVizszN	M3LFPFI2OTN7M{i3
UD-SCC2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVvnbmhiPzJiaB?=	M1TlUGROW09?	NF\CS4xIUTVyPUK4JOKyKDJwOTFOwG0>	NEnJO4IzPTF\|OUO4Oy=>
UPCI:SCC90	MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkTJO\|IhcA>?	NEXYPZhFVVOR	MkPQS2k2OD14Lk[gxtEhOS53IN88US=>	Ml\xNlUyOzl\|OEe=
RPMI-8226	MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NYX0cWdqOTJ3L{K1NE82ODBibl2=	M1jw[VQ5cMLi	NULNOGhbTE2VTx?=	M3zXbIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NHjyXHczPTByOEKwNi=>
OPM-2	NGLySHhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M2n6U\|EzPS9{NUCvOVAxKG6P	NEfKOFg1QGkEoB?=	MXPEUXNQ	M4HNcIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NUX2eY45OjVyMEiyNFI>
RPMI-8226	NWm0e4t6SXCxcITvd4l{KEG\|c3H5	NXHpOVJxOTJ3L{K1NE82ODBibl2=	NF;qR4s1QGkEoB?=	NVHvTWFwTE2VTx?=	NWfxPI5zcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MYqyOVAxQDJyMh?=
OPM-2	M2LEVGFxd3C2b4Ppd{BCe3OjeR?=	NH\Ee\|QyOjVxMkWwM\|UxOCCwTR?=	MY[0PIjDqA>?	MVLEUXNQ	M1;EfIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MoTwNlUxODh{MEK=
COG-LL-319	M1frPWZ2dmO2aX;uJGF{e2G7	M3n5[FExOCCwTR?=	MWWxM\|MwPiCq	NFnPbHVFVVOR	MYjpcoR2[2W\|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm	M4izTlI1QTVzNEey
RS4;11	NGfjNoFHfW6ldHnvckBCe3OjeR?=	MWSxNFAhdk1?	MVuxM\|MwPiCq	MmLoSG1UVw>?	NGHjcZhqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen	MViyOFk2OTR5Mh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

In vivo

In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. ^[1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. ^[2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Fluorescence polarization assays: Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research: ^[4]	+ Expand Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 Concentrations: 0.001-10 μM Incubation Time: 48 hours Method: SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%) Dosages: 20 and 30 mg/kg Administration: For intraperitoneal (i.p.) every day (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% Propylene glycol, 5% Tween 80, 65% D5W For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download ABT-737 SDF

Molecular Weight	813.43
Formula	C₄₂H₄₅ClN₆O₅S₂
CAS No.	852808-04-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommended method about reconstitution of the compound for in vivo animal study?
Answer:
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 101 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 101 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)